查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1169093

预防性疫苗市场：按疫苗类型、疾病类型（肺炎球菌,脊髓灰质炎病毒,肝炎,流感,麻疹,腮腺炎,风疹,其他）,地区-规模,份额,前景,机会分析2022-2028

Preventive Vaccines Market, By Vaccine Type, By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Mumps, and Rubella, and Other Disease Types), and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 173 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预防性疫苗可保护人们免受严重和危及生命的感染。 这些疫苗可帮助免疫系统更快、更有效地对抗感染。 疫苗是预防儿童和成人严重疾病的最有效方法之一。 因此，随着传染病流行的加剧，全球对预防性疫苗的需求也在迅速增加。

市场动态

预计在预测期内将发生几次传染病流行、疫苗接种需求增加、COVID-19 爆发、加强疫苗研发的举措不断增加以及对疫苗开发的关注度增加。这是预计推动增长的主要因素全球预防性疫苗市场的增长。

例如，美国和德国在 COVID-19 疫苗研发方面的投资最大，分别投入约 20 亿美元和 15 亿美元。 辉瑞和 BioNTech 在美国开发了第一个获得许可的 COVID-19 疫苗，已获得约 8 亿美元的研发资金。 此外，2022 年 1 月，Daiichi Sankyo Co., Ltd. 宣布已在日本开始试验，以研究针对新型冠状病毒感染（COVID-19）的 mRNA 疫苗 DS-5670 的加强给药。

这项研究的主要特点

  • 本报告对全球预防性疫苗市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2028 年）的市场规模和復合年增长率 (CAGR%)。
  • 它还揭示了不同细分市场的潜在创收机会，并为市场勾勒出一个有吸引力的投资建议矩阵。
  • 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
  • 它根据以下参数介绍了全球预防性疫苗市场的主要参与者，包括公司亮点、产品组合、主要亮点、财务业绩和战略。
  • 本研究涵盖的主要公司包括赛诺菲公司、辉瑞公司、Novavax 公司、默克公司、强生公司、葛兰素史克公司、第一三共株式会社、Emergent BioSolutions Inc.、阿斯利康和武田製药有限公司等。
  • 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 《全球预防疫苗市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以通过用于分析全球预防性疫苗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第二章市场展望

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 市场概况：按疫苗类型分类
    • 按疾病类型划分的市场概况
    • 市场概况：按地区
  • 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

  • 市场动态
    • 世界上传染病的增加
    • 疫苗开发成本高
    • COVID-19 爆发（全球大流行）
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/批准
  • 害虫分析
  • 对 PORTER 的分析
  • 合併/收购场景

第 4 章全球预防性疫苗市场：冠状病毒 (COVID-19) 大流行的影响

  • COVID-19 的流行病学
  • 供应方和需求方分析
  • 经济影响

第 5 章全球预防性疫苗市场：按疫苗类型分类，2017-2028

  • 活疫苗/减毒疫苗
  • 灭活□□疫苗
  • 亚单位疫苗
  • 类毒素疫苗
  • 其他疫苗类型

第 6 章全球预防性疫苗市场：按疾病类型分类，2017-2028

  • 肺炎球菌
  • 脊髓灰质炎病毒
  • 肝炎
  • 流感
  • 麻疹、腮腺炎和风疹 (MMR)
  • 其他疾病类型

第 7 章。全球预防性疫苗市场：按地区划分，2017-2028

  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
  • 世界其他地方

第八章竞争格局

  • Sanofi SA
  • Pfizer Inc.
  • Novavax Inc.
  • Merck & Co. Inc.
  • Johnson & Johnson
  • GlaxoSmithKline PLC,
  • Daiichi Sankyo Co. Ltd.
  • Emergent BioSolutions Inc.
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited

第九章

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI5342

Preventive vaccines protect people from serious and life-threatening infectious diseases. These vaccines help immune system fight infections faster and more effectively. Vaccines are one of the most effective ways to prevent serious disease in children and adults. Therefore, with the increase in prevalence of infectious diseases, the demand for preventive vaccines is also increasing with the rapid pace around the world.

Market Dynamics:

Increase in prevalence of several infectious diseases, increase in demand for vaccination, outbreak of COVID-19, rising initiatives to enhance R&D of vaccines, and increase in focus on the vaccine development are major factors expected to drive growth of the global preventive vaccines market during the forecast period.

For instance, the United States and Germany have been the largest investors in COVID-19 vaccine R&D, pouring around US$ 2 billion and US$ 1.5 billion into the effort, respectively. Pfizer and BioNTech, who developed the first COVID-19 vaccine authorized in the U.S., received around US$ 800 million in R&D funding. Moreover, in January 2022, Daiichi Sankyo Company, Limited announced that it has initiated a trial in Japan to investigate a booster dose of DS-5670, an mRNA vaccine against the novel coronavirus infectious disease (COVID-19).

Key features of the study:

  • This report provides in-depth analysis of the global preventive vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global preventive vaccines market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Sanofi SA, Pfizer Inc., Novavax Inc., Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline PLC, Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., AstraZeneca, and Takeda Pharmaceutical Company Limited, among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global preventive vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preventive vaccines market.

Detailed Segmentation:

  • Global Preventive Vaccines Market By Vaccine Type:
    • Live/Attenuated Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • Toxoid Vaccines
    • Other Vaccine Types
  • Global Preventive Vaccines Market By Disease Type:
    • Pneumococcal
    • Poliovirus
    • Hepatitis
    • Influenza
    • Measles, Mumps, and Rubella (MMR)
    • Other Disease Types
  • Global Preventive Vaccines Market By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Sanofi SA
    • Pfizer Inc.
    • Novavax Inc.
    • Merck & Co. Inc.
    • Johnson & Johnson
    • GlaxoSmithKline PLC
    • Daiichi Sankyo Co. Ltd.
    • Emergent BioSolutions Inc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Vaccine Type
    • Market Snapshot, By Disease Type
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in prevalence of infectious diseases around the world
    • High cost of vaccine development
    • The outbreak of COVID-19 (global pandemic)
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Preventive Vaccines Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Preventive Vaccines Market, By Vaccine Type, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Live/Attenuated Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Inactivated Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Subunit Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Toxoid Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Vaccine Types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global Preventive Vaccines Market, By Disease Type, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Pneumococcal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Poliovirus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Hepatitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Influenza
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Measles, Mumps, and Rubella (MMR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Other Disease Types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

7. Global Preventive Vaccines Market, By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

8. Competitive Landscape

  • Sanofi SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novavax Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co. Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson & Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline PLC,
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Daiichi Sankyo Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Emergent BioSolutions Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us